Their cholesterol levels greatly improved...

The Acomplia weight loss medication has been the subject of new clinical testing done by its manufacturer Sanofi Aventis in France. The research that used lab rats saw that when the rodents were given tiny doses of the Acomplia obesity drug their cholesterol levels greatly improved and it was also noted that the drug could lessen liver damage.

The rats in the study were given Acomplia every day over an 8 week period and at the end of this the researchers said that the rats’ livers had not enlarged as much as other rats that were not given the drug. They also noted that the level of fat in the livers of the rats was lower too. They also examined the blood of the rats to assess liver damage and noted a positive result also. The researchers also said that there was less of a particular inflammation protein that is known to create insulin resistance and cirrhosis in the liver. The research appeared in the clinical journal called Hepatology.

The Acomplia drug is approved for sale in Europe by the EMEA, but recently was denied approval in America by the Food & Drug Administration. In America there were concerns that depressed people who took the Acomplia weight loss drug could suffer from further depression and people who have a history of depression should not use this obesity medication.

Acomplia is an appetite suppressant that works differently to most other appetite suppressants by acting on receptors in the brain that cause you to feel hungry. Basically the drug tricks you into thinking that you are not hungry and so as a result you eat less. The United Kingdom was the first nation in Europe to start selling the Acomplia weight loss medication and Sanofi Aventis say they are very pleased with the take up in the UK.